Compare TORM plc (TRMD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TORM plc vs State Street SPDR S&P Biotech ETF — how do they compare? TORM plc trades at $40.47 (market cap $4.12B), while State Street SPDR S&P Biotech ETF trades at $154.31 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2.5× TORM plc's market cap, and TORM plc pays a 11.03% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold TORM plc for 23 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| TRMD | XBI | |
|---|---|---|
Market Cap | $4.12B | $10.11B |
Volume | 2,863,116 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $41.05 | $169.55 |
52-Week Low | $19.39 | $104.99 |
Typical Hold Time | 23 Days | 37 Days |
Enterprise Value | $4.83B | — |
Dividend Yield | 11.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TRMD trades at $40.54, up 4.16% today, with a bullish technical signal from moving averages and strong profitability metrics including a 35.52% net income margin and 26.84% ROE. Recent earnings showed a Q2 2026 miss but a Q4 2025 beat, while 2026 revenue is projected to grow to $1.8B. A $2.40 dividend is scheduled for September 2026, and analyst consensus is unanimously bullish with 3 buy ratings.
The outlook is positive given robust fundamentals and analyst support, but risks include spot rate volatility in the tanker market and recent insider selling. Upside potential hinges on sustained freight rates, while a downturn could pressure earnings. The stock presents a value opportunity with a low P/E of 6.59, though cyclical industry exposure warrants caution.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
